Gilead Sciences announced that the combination of its cancer drug Trodelvy and Merck’s Keytruda slowed tumor growth in women with an aggressive form of breast cancer. The findings from the randomized Phase 3 ASCENT-04 study may offer a new treatment for patients with newly diagnosed, metastatic, triple-negative breast cancer. This could also enhance Trodelvy sales for Gilead, which is currently competing with a similar drug by AstraZeneca and Daiichi Sankyo. The study showed a “clinically meaningful” improvement in progression-free survival when comparing Trodelvy and Keytruda to Keytruda plus chemotherapy, achieving the study’s main efficacy objective.
— new from statnews.com
